Assessing safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumors (NETs): The phase II LOLA trial.

Published on May 20, 2021in Journal of Clinical Oncology32.956
· DOI :10.1200/JCO.2021.39.15_SUPPL.TPS4167
Source
Abstract
References0
Newest
Cited By0
Newest